Approach: Developing antigen-specific immune tolerance therapies for autoimmune and allergic diseases
Strategic Area: Immunotherapies
T1D Funding Impact: Catalyzing company formation and T1D program, together with a pharmaceutical company partner
Strategic Area: Immunotherapies
T1D Funding Impact: Catalyzing company formation and T1D program, together with a pharmaceutical company partner
Employees: 11-50
Total raised: $4M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.09.2016 | Series A | $4M | - |
Mentions in press and media 2
| Date | Title | Description |
| 08.09.2016 | Pfizer seeds diabetes upstart AnTolRx with cash and an option deal | Pfizer is backing a newly minted biotech that is right at the very earliest stage of taking an academic program out of a Harvard lab and seeing if it can translate it into a successful development effort for Type 1 di... |
| 08.09.2016 | AnTolRx Closes Series A Funding Totalling $4M | AnTolRx, Inc., a Cambridge, Mass.-based developer of treatment of autoimmune diseases, closed a Series A funding agreement totalling $4m over two next two years. The round was led by Pfizer (NYSE: PFE), with participation from Orion Equity ... |